185 related articles for article (PubMed ID: 33850538)
1. Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma.
Sobol NT; Solernó LM; Beltrán B; Vásquez L; Ripoll GV; Garona J; Alonso DF
Exp Ther Med; 2021 Jun; 21(6):566. PubMed ID: 33850538
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.
Garona J; Sobol NT; Pifano M; Segatori VI; Gomez DE; Ripoll GV; Alonso DF
Cancer Res Treat; 2019 Apr; 51(2):438-450. PubMed ID: 29879760
[TBL] [Abstract][Full Text] [Related]
3. Development and therapeutic potential of vasopressin synthetic analog [V
Garona J; Pifano M; Ripoll G; Alonso DF
Vitam Horm; 2020; 113():259-289. PubMed ID: 32138951
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin Analog [V
Sobol NT; Solerno LM; Llavona C; Alonso DF; Garona J
World J Oncol; 2023 Dec; 14(6):540-550. PubMed ID: 38022396
[TBL] [Abstract][Full Text] [Related]
5. The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.
Garona J; Pifano M; Orlando UD; Pastrian MB; Iannucci NB; Ortega HH; Podesta EJ; Gomez DE; Ripoll GV; Alonso DF
Int J Oncol; 2015; 46(6):2335-45. PubMed ID: 25846632
[TBL] [Abstract][Full Text] [Related]
6. Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.
Garona J; Pifano M; Pastrian MB; Gomez DE; Ripoll GV; Alonso DF
Clin Exp Metastasis; 2016 Aug; 33(6):589-600. PubMed ID: 27146156
[TBL] [Abstract][Full Text] [Related]
7. Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.
Pifano M; Garona J; Capobianco CS; Gonzalez N; Alonso DF; Ripoll GV
Front Oncol; 2017; 7():11. PubMed ID: 28194370
[TBL] [Abstract][Full Text] [Related]
8. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.
Ripoll GV; Garona J; Pifano M; Farina HG; Gomez DE; Alonso DF
Breast Cancer Res Treat; 2013 Nov; 142(1):9-18. PubMed ID: 24122393
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.
Iannucci NB; Ripoll GV; Garona J; Cascone O; Ciccia GN; Gomez DE; Alonso DF
Future Med Chem; 2011 Dec; 3(16):1987-93. PubMed ID: 22098349
[TBL] [Abstract][Full Text] [Related]
10. Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.
Solernó LM; Sobol NT; Gottardo MF; Capobianco CS; Ferrero MR; Vásquez L; Alonso DF; Garona J
Sci Rep; 2022 Sep; 12(1):15058. PubMed ID: 36075937
[TBL] [Abstract][Full Text] [Related]
11. Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer.
Ripoll GV; Garona J; Hermo GA; Gomez DE; Alonso DF
Anticancer Res; 2010 Dec; 30(12):5049-54. PubMed ID: 21187489
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment.
Chevalier MT; Garona J; Sobol NT; Farina HG; Alonso DF; Álvarez VA
Nanomedicine (Lond); 2018 Nov; 13(22):2835-2849. PubMed ID: 30430901
[TBL] [Abstract][Full Text] [Related]
13. Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice.
Garona J; Pifano M; Scursoni AM; Gomez DE; Alonso DF; Ripoll GV
Anticancer Res; 2014 Sep; 34(9):4761-5. PubMed ID: 25202055
[TBL] [Abstract][Full Text] [Related]
14. Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.
Heidman LM; Peinetti N; Copello VA; Burnstein KL
Mol Cancer Res; 2022 Aug; 20(8):1295-1304. PubMed ID: 35503085
[TBL] [Abstract][Full Text] [Related]
15. Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial.
Iseas S; Roca EL; O'Connor JM; Eleta M; Sanchez-Luceros A; Di Leo D; Tinelli M; Fara ML; Spitzer E; Demarco IA; Ripoll GV; Pifano M; Garona J; Alonso DF
Invest New Drugs; 2020 Oct; 38(5):1580-1587. PubMed ID: 32166534
[TBL] [Abstract][Full Text] [Related]
16. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling.
Kaufmann JE; Iezzi M; Vischer UM
J Thromb Haemost; 2003 Apr; 1(4):821-8. PubMed ID: 12871421
[TBL] [Abstract][Full Text] [Related]
17. Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.
Giron S; Tejera AM; Ripoll GV; Gomez DE; Alonso DF
J Surg Oncol; 2002 Sep; 81(1):38-44. PubMed ID: 12210026
[TBL] [Abstract][Full Text] [Related]
18. A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers.
Schernthaner-Reiter MH; Adams D; Trivellin G; Ramnitz MS; Raygada M; Golas G; Faucz FR; Nilsson O; Nella AA; Dileepan K; Lodish M; Lee P; Tifft C; Markello T; Gahl W; Stratakis CA
Eur J Pediatr; 2016 May; 175(5):727-33. PubMed ID: 26795631
[TBL] [Abstract][Full Text] [Related]
19. Oral disintegrating desmopressin tablet is effective for partial congenital nephrogenic diabetes insipidus with
Ikegawa K; Hachiya R; Akiba K; Hasegawa Y
Clin Pediatr Endocrinol; 2022; 31(2):87-92. PubMed ID: 35431445
[TBL] [Abstract][Full Text] [Related]
20. Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene.
Faerch M; Christensen JH; Corydon TJ; Kamperis K; de Zegher F; Gregersen N; Robertson GL; Rittig S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):395-403. PubMed ID: 17941907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
